RESURGENCE OF BISPECIFIC ANTIBODIES - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 521

66. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop
S, et al. (2008) Tumor regression in cancer patients by very low
doses of a T cell-engaging antibody. Science 321, 974-977.
67. Stein C, Kellner C, Kugler M, Reiff N, Mentz K, Schwenkert
M, et al. (2010) Novel conjugates of single-chain Fv antibody
fragments specific for stem cell antigen CD123 mediate potent
death of acute myeloid leukaemia cells. Br. J. Haematol. 148,
879-889.
68. Schubert I, Kellner C, SteinC, KuglerM, SchwenkertM, Saul D,
et al. (2011) A single-chain triplebody with specificity for CD19
and CD33 mediates effective lysis of mixed lineage leukemia
cells by dual targeting. MAbs, 1, 3 [Epub ahead of print].
69. Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M,
Horner H, et al. (2010) A recombinant bispecific single-chain
fragmentr variable specific for HLA class II and Fc alpha RI
(CD89) recruits polymorphonuclear neutrophils for efficient
lysis of malignant B lymphoid cells. J.

binding domain (ABD) on the half-life of a single-chain
diabody-ABD fusion protein. Protein Eng. Des. Sel. 23, 827-
834.
78. Noy R, Eppel M, Haus-Cohen M, Klechevsky E, Mekler O,
Michaeli Y, et al. (2005) T-cell receptor-like antibodies: novel
reagents for clinical cancer immunology and immunotherapy.
Expert Rev. Anticancer Ther. 5, 523-536.
79. Drummond D. (2010) Drug Discovery and Development
Week, Burlingame, CA, 2010 August 2-4.
80. Zhu X, Wang L, Liu R, Flutter B, Li S, Ding J, et al. (2010)
COMBODY: one-domain antibody multimer with improved
avidity. Immunol. Cell Biol. 88, 667-675.
81. Shusterman SS, London, WB, Gillies SD, Hank, JA, Voss, SD,
Seeger, RC, et al. (2010) Antitumor activity of Hu14.18-IL2 in
patients with relapsed/refractory neuroblastoma: a children's
oncology group (COG) Phase II study. J. Clin. Oncol. October
4 [Epub ahead of print].
82. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S,
Kempkensteffen C, et al. (2010) Eur. J. Cancer 46, 2926-2935.
83. Robinson MK, Alpaugh RK, Borghaei H. (2010) Naptumomab
estefenatox: a new immunoconjugate. Expert Opin. Biol. Ther.
10, 273-279.
84. Cheng JD, Babb JS, langer C, Aamdal S, Robert F, Engelhardt
LR, et al. (2004) Individualized patient dosing in Phase I
clinical trials: the role of escalation with overdose control in
PNU-214936. J. Clin. Oncol. 22, 602-609.
85. Liddy N, Molloy PE, Bennett AD, Boulter JM, Jakobsen BK,
Li Y. (2010) Production of a soluble disulfide-linked TCR in
the cytoplasm of Escherichia coli trxB got mutants. Mol.
Biotechnol. 45, 140-149.
86. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida
K, kakita S, et al. (2004) Fucose depletion from human IgG1
oligosaccharide enhances binding enthalpy and association
rate between IgG1 and FcgammaRIIIa. J. Mol. Biol. 336,
1239-1249.
87. Bugelski PJ, Achuthanadam R, Capocascale RJ, Treacy G,
Bouman-Thio E. (2009) Monoclonal antibody-induced cyto-
kine-release syndrome. Expert Rev. Clin. Immunol. 5, 499-521.
88. Dohlsten M, Hedlund G, Kalland T. (1991) Staphylococcal-
enterotoxin-dependent cell-mediated cytotoxicity. Immunol.
Today 12, 147-150.
89. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S,
Rattel B, et al. (2010) T cell-engaging BiTE antibodies specific
for EGFR potently eliminate KRAS- and BRAF-mutated
colorectal cancer cells. Proc. Natl. Acad. Sci. USA 107,
12605-12610.
90. Purbhoo MA, Irvine DJ, Huppa JB, Davis MM. (2004) T cell
killing does not require the formation of a stable mature
immunological synapse. Nat. Immunol. 5, 524-530.

Immunol. 184,

1210-1217.
70. Le Gall F, Reusch U, Little M, Kipriyanov SM. (2004) Effect
of linker sequences between the antibody variable domains on
the formation, stability, and biological activity of a bispecific
tandem diabody. Protein Eng. Des. Sel. 17, 357-366.
71. reusch U, Le Gall F, Hensel M, Moledenhauer G, Ho AD, Little
M, et al. (2004) Effect of tetravalent bispecific CD19xCD3
recombinant antibody construct and CD28 costimulation on
lysis ofmalignant B cells frompatientswith chronic lymphocytic
leukemia by autologous T cells. Int. J. Cancer 112, 509-518.
72. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little
M. (1999) A bispecific diabody that mediates natural killer cell
cytotoxicity against xenotransplanted human Hodgkin's
tumors. Blood 94, 2562-2568.
73. Cochlovius B, Kipiriyanov SM, Stassar MJ, Schuhmacher J,
Bener A, Moldenhauer G, et al. (2000) Cure of Burkitt's
lymphoma in severe combined immunodeficiency mice by
T cells, tetravalent CD3 CD19 tandem diabody, and CD28
costimulation. Cancer Res. 60, 4336-4341.
74. Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang H, et al.
(2010) Effector cell recruitment with novel Fv-based dual-
affinity retargeting proteins leads to potent tumor cytolysis and
in vivo B-cell depletion. J. Mol. Biol. 399, 436-449.
75. Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, et al.
(2010) Therapeutic control of B cell activationvia recruitment of
Fcgamma receptor IIb (CD32B) inhibitory function with a novel
bispecific antibody scaffold. Arthritis Rheum. 62, 1933-1943.
76. Villani ME, Di Carli M, Donini M, Traversini G, Lico C,
Franconi R, et al. (2008) Validation of a stable recombinant
antibodies repertoire for the direct selection of functional
intracellular reagents. J. Immunol. Methods 329, 11-20.
77. Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, Muller D,
et al. (2010) The effects of affinity and valency of an albumin-